VK2735
VK2735 is a dual agonist of the GIP receptor and GLP-1 receptor,[1] with a similar mechanism of action to that of tirzepatide ‒ a drug for diabetes.[1] It can be injected via human skin.[1] It is made by the pharmaceutical company Viking Therapeutics.[1]
References
- ↑ 1.0 1.1 1.2 1.3
- Mariam E Sunny, Bhanvi Satija. Viking Therapeutics notches success with weight-loss drug trial, shares double. Reuters (2024-02-27). Retrieved 2024-03-09.
- Goldenberg, Ronald M.. Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data. Current Opinion in Cardiology 38 (6) (2023-08-21)Ovid Technologies (Wolters Kluwer Health). p. 539–545. doi:10.1097/hco.0000000000001084.
- Goldenberg, Ronald M.. Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists. Obesity Reviews 25 (3) (2024). p. e13663. doi:10.1111/obr.13663.
